Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by askretkaon Sep 23, 2022 8:35am
204 Views
Post# 34981208

Treatment 's considered Holy Grail of Oncology

Treatment 's considered Holy Grail of Oncology
" Unfortunately, the vast majority of pancreatic and colorectal cancers are resistant to currently available immunotherapies. Because of this, developing effective immunotherapeutic strategies directed against immunologically cold malignancies, like pancreatic and colorectal cancer, is a widely considered one of the holy grails of modern oncology, said Cleary" ------------------------------------------ https://www.google.com/amp/s/www.forbes.com/sites/victoriaforster/2021/04/24/scientists-predict-rise-in-deaths-from-pancreatic-cancer-and-young-onset-colorectal-cancer/amp/
<< Previous
Bullboard Posts
Next >>